Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Ocular Disease Models
Advance your vision research with our scientifically validated disease models that faithfully mimic human ocular conditions. Streamline timelines, generate reliable data, and confidently translate your findings to accelerate breakthroughs in vision science.
Phenotypic Characteristics
Models exhibit well-defined phenotypic characteristics to facilitate targeted investigations.
Mapping Stable Genetic Traits
Each model features stable, heritable genetic traits for reliable experimental outcomes.
Diverse Disease Coverage
Models cover conditions like retinitis pigmentosa, macular degeneration, and corneal dysfunction.
Overview
Product
FAQs
Overview
Ophthalmic Disease Models: Accelerating Vision Research
Cyagen's validated genetic eye disease models deliver precise research tools for ophthalmology breakthroughs. Our portfolio includes models for retinitis pigmentosa, macular degeneration, and LCA, backed by specialized phenotype analysis services to fast-track your preclinical studies.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
Ophthalmic CRO Platform
Ocular disease models and IND-ready drug evaluation workflows
AI-Powered AAV Discovery
Accelerate gene therapy with AI-optimized AAV capsid engineering and testing
Rodent Breeding
Scalable colony expansion with full genotyping support
Rodent Phenotyping
Full-spectrum analysis for rodents model
Gene Therapy CRO Platform
AI-guided AAV design and full-spectrum preclinical validation
Product
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Quantity
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Selection Made Simple
Access Our Model Library >>
Base Strain
Catalog Number
Catalog NumberNameBase StrainResearch ApplicationAction
C001360B6-Rpe65 R44XC57BL/6JCyaRetinitis pigmentosa 20 (RP20) research;Leber's congenital amaurosis type 2 (LCA2) research;The visual cycle research
C001384Pde6b KOC57BL/6JCyaRetinitis Pigmentosa (RP) Research;Congenital Stationary Night Blindness (CSNB) Research;Other Eye Disease Research
C001385Prph2 KOC57BL/6JCyaRetinitis Pigmentosa (RP) Research;Age-related Macular Degeneration (AMD) Research;Macular Dystrophy (MDs) Research
C001386Tub KOC57BL/6JCyaRetinal Degeneration (RD) Research;Obesity Mechanism Research;Other Retinal and Hearing Diseases Research
C001387Rpe65 KOC57BL/6JCyaRetinal Degeneration (RD) Research;Leber Congenital Amaurosis 2 (LCA2) Research;Other Retinal Disease Research
C001395hVEGFA-TGC57BL/6JCyaResearch on Age-Related Macular Degeneration (AMD);Research on Diabetic Retinopathy (DR);Research on corneal neovascular diseases
C001425Nr2e3 KOC57BL/6JCyaEnhanced S-Cone Syndrome (ESCS) Research;Retinitis Pigmentosa (RP) Research;Other Retinal Diseases Research
I001134Abca4 KOC57BL/6JCyaResearch on Stargardt Disease (STGD);Research on Cone-rod Dystrophy (CRD);Research on Retinitis Pigmentosa (RP)
C001700Rho KOC57BL/6JCyaResearch on retinitis pigmentosa (RP);Research on congenital stationary night blindness (CSNB);Research on other retinal diseases
C001823Rpgr KOC57BL/6JCyaResearch on X-linked retinitis pigmentosa (XLRP);Research on X-linked cone-rod dystrophy (CORDX1);Research on other retinal diseases
Items: 1 to 10 of 29
1
2
3
Previous Page
Next Page
FAQs
Frequently Asked Questions (FAQs)
What customization options do you consider essential when developing a mouse model for a specific ocular disease?
Essential customization options include selecting specific genetic backgrounds, modifying gene expression levels, and tailoring phenotypic traits to align with the research objectives. We work closely with clients to ensure that the model meets their precise experimental needs.
How have your findings from these mouse models translated into potential therapeutic strategies or clinical applications for ocular diseases?
Our collaborations with researchers have led to significant advancements in gene therapy and pharmacological interventions. For example, studies using our models have contributed to the development of gene therapies that are currently undergoing clinical trials, showcasing the translational potential of our work.
Can you share your validation processes for ensuring that the mouse models accurately reflect the clinical aspects of the diseases being studied?
We employ rigorous validation processes that include phenotypic characterization, functional assessments, and comparisons with clinical data. This ensures that our models exhibit the same pathological features observed in human patients, providing confidence in their utility for research.
Which genetic modifications have you implemented in your mouse models to better mimic human ocular conditions?
Our mouse models often include genetic modifications such as knockouts or transgenic alterations relevant to specific ocular diseases. For instance, we utilize models with mutations in genes like RPE65 or ABCA4, which are associated with inherited retinal diseases, to provide a more accurate representation of human conditions.
What specific ocular disease models do you find most effective in replicating the pathophysiology of retinal diseases?
At Cyagen, we offer a range of ocular disease models, including those for retinal degeneration, diabetic retinopathy, and age-related macular degeneration. These models are designed to closely mimic the human disease state, allowing researchers to study the underlying mechanisms and test potential therapies effectively.
What are the lead times for developing custom neurological disease models, especially for less common conditions like frontotemporal dementia?
The lead time for developing custom neurological disease models can vary depending on the complexity of the genetic modifications and the specific disease. For less common conditions like frontotemporal dementia, we typically require 6 to 12 months from project initiation to delivery, assuming standard genetic engineering techniques are used. Complex models might take longer. We encourage early consultation to discuss project specifics and timelines.
What Customers Say About Cyagen
Violet Shimmer
Stanford University
The service provided to us by Cyagen is now in press at Nature as an article.
Scarlett Rouge
Seattle Children’s Hospital
We are very pleased with the state-of-the-art professional transgenic services provided by Cyagen for our study published recently in Nature. We continue to use Cyagen’s transgenic services as it allows us to do better and more efficient research with transgenic mice.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest